Epidemiology, management and treatment outcome of medulloblastoma in singapore.
- Author:
Mei-Yoke CHAN
1
;
Wan-Yee TEO
;
Wan-Tew SEOW
;
Ah-Moy TAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Child; Child, Preschool; Disease Management; Female; Humans; Infant; Male; Medulloblastoma; epidemiology; physiopathology; therapy; Outcome Assessment (Health Care); Registries; Retrospective Studies; Singapore; epidemiology; Survival Rate
- From:Annals of the Academy of Medicine, Singapore 2007;36(5):314-318
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONMedulloblastoma/primitive neuroectodermal tumour is the most common type of malignant brain tumour in children. Long-term survival rates have improved over the years with a combination of surgical, radiotherapeutic and chemotherapeutic treatment modalities in the developed world. This paper aims to analyse the epidemiology and outcome of medulloblastoma in Singapore and compare our results with those reported in the literature.
MATERIALS AND METHODSA 9-year retrospective study was done using data reported to the Singapore Children's Cancer Registry from June 1997 to June 2005. Only 39 children up to the age of 15 years diagnosed histologically with medulloblastoma or primitive neuroectodermal tumour arising from the cerebellum were included in the study. Follow-up data were collected up to June 2006 and analysed using SPSS v 13.0 software.
RESULTSMedulloblastoma/primitive neuroectodermal tumour was the most common type of brain tumour, accounting for 40.7% of all brain tumours diagnosed in children in Singapore. The 5-year event-free survival rate was 44.5%, while the 5- year overall survival rate was 51.5%. Nearly half (41%) of our patients had spinal metastasis at presentation and this was associated with a worse event-free survival (6.3% vs 71.9%, P = 0). Children under 36 months of age had a significantly poorer overall survival (28.8% vs 52.2%, P = 0.041).
CONCLUSIONSThe outcome of medulloblastoma in Singapore was inferior to reported figures in the literature. We need to close identified gaps in care, like standardising assessment and treatment protocols, in order to improve our results. Research into molecular and genetic characteristics may also throw light on whether the disease is inherently more aggressive in our population.